Table 2 Laboratory findings of patients with COVID-19 on admission to hospital
From: Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19
| Normal range | Mild cases (N = 89) | Severe cases (N = 62) | P | |
|---|---|---|---|---|
| White blood cell count, × 109/L | 3.5–9.5 | 4.9 (2.0) | 7.3 (6.7) | 0.000 |
| Neutrophil count, × 109/L | 1.8–6.3 | 3.0 (2.1) | 5.8 (7.1) | 0.000 |
| Lymphocyte count, × 109/L | 1.1–3.2 | 1.2 ± 0.5 | 0.8 ± 0.4 | 0.000 |
| Alanine aminotransferase, U/L | ≤ 33 | 28 ± 32 | 34 ± 27 | 0.266 |
| Aspartate aminotransferase, U/L | ≤ 32 | 24.0 (13.0) | 36.0 (26.0) | 0.000 |
| Lactate dehydrogenase, U/L | 135–214 | 251.0 (93.0) | 431.5 (367.0) | 0.000 |
| Creatinine, μmol/L | 45–84 | 70.0 (28.5) | 81.5 (33.0) | 0.003 |
| Uric acid, μmol/L | 202.3–416.6 | 248.0 (103.9) | 264.5 (168.9) | 0.036 |
| Total cholesterol, mmol/L | < 5.18 | 3.8 ± 0.7 | 3.6 ± 0.8 | 0.089 |
| C-reactive protein, mg/L | < 1 | 12.6 (36.4) | 68.7 (114.6) | 0.000 |
| Erythrocyte sedimentation rate, mm/H | 0–20 | 28 ± 22 | 32 ± 22 | 0.477 |
| Ferritin, ug/L | 15–150 | 888.2 ± 2181.7 | 1869.1 ± 2229.4 | 0.027 |
| TNFα, pg/mL | < 8.1 | 7.3 (3.3) | 9.1 (6.0) | 0.002 |
| HbA1c, % | 4–6 | 6.0 ± 1.5 | 6.7 ± 2.1 | 0.083 |
| Fasting glucose, mmol/L | 4.11–6.55 | 6.2 (2.3) | 8.4 (5.8) | 0.000 |
| Triglyceride, mmol/L | < 1.7 | 1.4 ± 1.0 | 1.5 ± 0.6 | 0.431 |
| TyG | – | 8.7 ± 0.6 | 9.2 ± 0.6 | 0.000 |